购物车
- 全部删除
- 您的购物车当前为空
AGN 194310 (VTP-194310) is retinioic acid receptors (RARs) pan-antagonist. The Kd values of 3 nM, 2 nM, 5 nM for RARα, RARβ, RARγ, respectively[1][2].
为众多的药物研发团队赋能,
让新药发现更简单!
AGN 194310 (VTP-194310) is retinioic acid receptors (RARs) pan-antagonist. The Kd values of 3 nM, 2 nM, 5 nM for RARα, RARβ, RARγ, respectively[1][2].
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 4,570 | 8-10周 | |
25 mg | ¥ 14,300 | 8-10周 | |
50 mg | ¥ 18,700 | 8-10周 | |
100 mg | ¥ 25,500 | 8-10周 | |
1 mL x 10 mM (in DMSO) | ¥ 4,930 | 8-10周 |
产品描述 | AGN 194310 (VTP-194310) is retinioic acid receptors (RARs) pan-antagonist. The Kd values of 3 nM, 2 nM, 5 nM for RARα, RARβ, RARγ, respectively[1][2]. |
靶点活性 | RARα:3 nM (kd), RARβ:2 nM (kd), RARγ:5 nM (kd) |
体外活性 | AGN194310 potently inhibits colony formation by all three lines, with IC50 values of 16 nM for LNCaP cells; 18 nM for PC3 cells; and 34 nM for DU-145 cells[2]. AGN 194310 (50 nM, 100 nM; LNCaP, PC-3 and DU-145 cells) inhibits colony formation at concentrations of 50 nM and 100 nM alone and in combination with TTNPB[2]. AGN 194310 (1 μM; 72 hours; LNCaP cells) treatment results in 80% apoptosis[2]. |
体内活性 | AGN 194310 (0.5 mg/kg/day; oral gavage; every day; for 10 days; female C57Bl/6J mice) treatment increases the number of granulocytes across haemopoietic compartments. A significant increase in the frequency of granulocyte-progenitor cells is observed in the bone marrow of mice after treatment with AGN194310[3]. |
别名 | VTP-194310 |
分子量 | 424.55 |
分子式 | C28H24O2S |
CAS No. | 229961-45-9 |
密度 | 1.26 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (117.77 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容